Audit: QRS - Cold Exposure for Health & Longevity

Audit conducted on 31/08/2026 02:53 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol cells, benefit/risk tiers, all 9 monitoring rows and all 7 qualitative items trace to explicit ER text.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No established numeric target” (marker 8) and “No established target” (marker 9) are carried verbatim; at-a-glance keeps “less certain” for the sleep/stress claims.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Both ER “Absolute contraindication” interactions (sedatives/alcohol, breath-holding) are placed in Contraindications, not Key Interactions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from Key Interactions & Contraindications; tiers only from Expected Benefits / Potential Risks & Side Effects; markers only from Monitoring Protocol & Defining Success.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Scan of the QRS body returns no PMID, NCT identifier, author name or brand name.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, hedged register matches the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and protocol ranges paired with plain-language framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as observed findings and ranges, not instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No directives; monitoring values sit under the template’s fixed “Target” header.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise” or “should” in the document’s own voice; the single “should” (line 853) is ER-verbatim descriptive text about symptom resolution.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Clinical terms retained only where they are the decision-relevant precision (NYHA class, long QT, HOMA-IR); at-a-glance is fully plain.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lines, gate items and marker cells are all reduced to key facts.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — all items are noun phrases or impersonal fragments.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Full 12-item contraindication gate and 9-marker panel assume a risk-aware, proactive reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol presents 2–4 weekly immersions and a baseline lab panel without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward casual practice; the ECG and thyroid-panel entries are retained.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance leads with the muscle-building conflict and the drowning mechanism — the two costs that matter most to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal register maintained (“myocardial infarction”, “peripheral neuropathy”, “non-freezing cold injury”); plain wording in at-a-glance is required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Set comparison of template vs QRS variable names returns no missing name; marker_#/qualitative_item_# rows are expanded to 9 and 7 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" are unchanged; a line-by-line diff of the head/CSS block against the template shows only the page_title substitution.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard immersion protocol”, “Cold shower approach” and “Best time of day” are the ER’s bold labels verbatim; all 9 marker names match the ER table’s Biomarker column exactly.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Soreness and perceived recovery”, “Energy expenditure”, “Metabolic adaptation”) are all ER vocabulary drawn from the corresponding benefit headings and the ER’s Time to effect bullet.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Non-ASCII scan of the body returns only en dash, em dash, degree sign, micro sign and multiplication sign — no emoji; the ER’s “⚠️ Conflicted” marker is correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is materially condensed against the ER: the Monitoring table drops the ER’s entire Context/Notes column, gate items drop all explanatory glosses, and benefit/risk tiers are reduced to bare headings.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated anywhere in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon requiring it.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: cold_exposure_2026-0831-0009_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0831-0246.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename cold_exposure_2026-0831-0009_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Confirmed across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Cold Exposure for Health & Longevity - Quick Reference Sheet” (line 22), with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Cold Exposure for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0831-0246 → “08/31/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block matches the template exactly; the ER’s long “Also known as” list is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Mirrors the Conclusion’s structure: best-supported effects, thinner claims, then the concrete costs.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence (ER lines 497–498).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “involuntary gasp”, “heat production”, “blood sugar and insulin” replace the ER’s technical framing.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 12 items originate in ER lines 321–350.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 10 “Populations who should avoid” entries plus the two interaction bullets the ER flags “Absolute contraindication”.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Twelve <li> elements inside the stop_items span (lines 577–591).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Explanatory glosses stripped throughout (e.g., ER “Pregnancy, where no safety data on deliberate immersion exist” → “Pregnancy”); no dashes carrying trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 90 days”, “(at or above 180/110 mmHg)” and “New York Heart Association Class III or IV” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 7 items originate in ER lines 321–337.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 9 ER interaction bullets are accounted for: 7 here, and the 2 “Absolute contraindication” bullets correctly excluded to the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements inside the caution_items span (lines 599–614).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanistic rationale and mitigation sentences are all stripped; the ER’s “Supplement interactions —” and “Other interventions —” category prefixes are removed so only the key fact remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every named drug list is retained (metoprolol/propranolol/bisoprolol; amlodipine/lisinopril/losartan/hydrochlorothiazide; ibuprofen/naproxen/aspirin; pseudoephedrine/high-dose caffeine; and the six-supplement list).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies nine such entries and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol bullets at lines 374, 380 and 382.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose (temperature/duration/frequency), the low-barrier entry protocol, and timing — the three decision variables a reader must set before starting.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains twelve bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine sub-fields carry substantive ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Soreness/perceived recovery (next day), energy expenditure (immediate) and metabolic adaptation (~10 days) — the onset windows for the ER’s two High-tier and leading Medium-tier benefits.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER’s own benefit ranking: High (soreness), High (energy expenditure), Medium (insulin sensitivity).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Each sub-line traces to ER text (lines 155, 161, 177 and 425); no placeholders remain.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides a dedicated “Time to effect” bullet at line 425.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten tier entries correspond one-to-one with the ER’s benefit sub-headings (lines 153–213).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 543–567).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to bare ER headings; none of the ER’s Magnitude: figures, confidence intervals or study counts are carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit tier.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	The ER populates all four benefit tiers.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven tier entries correspond one-to-one with the ER’s risk sub-headings (lines 237–303).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 626–650).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to bare ER headings; the ER’s incidence figures and odds ratios are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk tier.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	The ER populates all four risk tiers.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows reproduce the ER biomarker table at lines 455–465.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 9 ER biomarkers are present with name, target and rationale reproduced verbatim; none dropped.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 806–810 condense the ER’s baseline / weekly-first-month / 12-week / 6–12-month schedule from lines 451 and 453.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items reproduce the ER’s “Qualitative markers worth tracking” list at lines 469–475.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 7 ER qualitative markers are present, verbatim, in the ER’s own order.

Issues 31/08/2026 02:53

Pass rate 100.00%. No issues found.